# Serge Messerlian

> Serge Messerlian is the Chairman and CEO of Creyon Bio, a San Diego biotech using AI to design oligonucleotide medicines. A life-science operator with more than 25 years across oncology, hematology, immunology and rare disease, he has led Teon Therapeutics as CEO, run Janssen Oncology as President at Johnson & Johnson, and held senior roles at Actelion, Baxalta and Baxter International. He joined Creyon first as an investor and board member through DCVC Bio, then stepped in as Executive Chairman and Acting CEO in fall 2024 and took the full CEO title in April 2025 as the company prepares to enter the clinic in 2026.

- **Role:** Chairman and CEO at Creyon Bio
- **Organizations:** Creyon Bio, DCVC Bio, Teon Therapeutics, Janssen (Johnson & Johnson), Actelion, Baxalta, Baxter International
- **Nationality:** Canadian
- **Education:** B.Sc. in Physiology and Biotechnology, McGill University, M.Sc. in Human/Molecular Genetics, McGill University, MBA, University of Toronto - Rotman School of Management
- **Known for:** Appointed CEO of Creyon Bio in April 2025 after serving as Executive Chairman and Acting CEO, Led Janssen Oncology (Johnson & Johnson) as President, overseeing hematology and solid tumor brands and cell therapy platforms, Co-founded and led Teon Therapeutics as CEO

## Career timeline

- **—** — Held executive leadership roles at Baxter International spanning product development and operations
- **—** — Executive leadership at Baxalta (M&A integration, business development)
- **—** — Executive leadership at Actelion, a Johnson & Johnson company
- **—** — President of Janssen Oncology (Johnson & Johnson), leading hematology and solid tumor brands, pipeline and cell therapy platforms
- **—** — Co-Founder and CEO of Teon Therapeutics, an immuno-oncology biotech
- **2024** — Operating Partner at DCVC Bio; joined Creyon Bio's Board of Directors as an investor and board member
- **2024** — Named Executive Chairman and Acting CEO of Creyon Bio (fall 2024)
- **2025** — Appointed Chief Executive Officer of Creyon Bio, effective April 23, 2025
- **2026** — Targeting entry into clinical development at Creyon Bio

## Achievements

- Appointed CEO of Creyon Bio in April 2025 after serving as Executive Chairman and Acting CEO
- Led Janssen Oncology (Johnson & Johnson) as President, overseeing hematology and solid tumor brands and cell therapy platforms
- Co-founded and led Teon Therapeutics as CEO
- Directed M&A integration and multi-billion-dollar operations across Baxter International, Baxalta and Actelion
- More than 25 years building value across immunology, hematology, oncology and rare disease

## Latest updates

- **2025-04** — Appointed Chief Executive Officer of Creyon Bio, effective April 23, 2025; Dr. Kiersten Stead of DCVC Bio joined the board.
- **2024-09** — Joined Creyon Bio as Executive Chairman and Acting CEO.

## Links

- Website: https://creyonbio.com
- LinkedIn: http://www.linkedin.com/in/serge-messerlian-59538a4

---

Profile page: https://yespress.io/serge-messerlian
Published by YesPress — https://yespress.io
Last updated: 2026-07-29